中国医药：子公司富马酸伏诺拉生化学原料药获批上市

Core Viewpoint - China Pharmaceutical announced that its wholly-owned subsidiary Tianfang Pharmaceutical received approval from the National Medical Products Administration for the listing application of fumaric acid volnorelaxin, which is primarily used for treating gastroesophageal reflux disease and eradicating Helicobacter pylori when used in conjunction with appropriate antibiotics [1] Group 1 - Tianfang Pharmaceutical has received the approval notice for fumaric acid volnorelaxin, indicating a significant advancement in its product pipeline [1] - The drug is intended for the treatment of gastroesophageal reflux disease and is used alongside antibiotics to eliminate Helicobacter pylori [1] - Additionally, Tianfang Pharmaceutical has obtained the European Pharmacopoeia suitability certificate for clindamycin phosphate, which is an antibiotic used for Gram-positive and anaerobic bacterial infections [1]